Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4

作者：Paul T. Golumbek, Audrey J. Lazenby, Hyam I. Levitsky, Liz Jaffee, Hajime Karasuyama, Mitzi Baker, Drew M. Pardoll · 发表于：Science · 年份：1991 · DOI：10.1126/science.1948050 · 被引用次数：730 · 研究领域：CAR-T cell therapy research、Cancer Research and Treatments、Virus-based gene therapy research

The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.